Chugai Pharmaceutical Co Ltd
4519: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥3,696.00 | Xhnhyd | Rxrfptrd |
Chugai's Second-Quarter Earnings In Line; Fair Value Estimate Unchanged at JPY 4,860
Narrow moat Chugai’s reported second-quarter earnings that were in line with our expectations. Top-line revenue was JPY 221 billion, or 17% higher than the same period last year, mostly due to increased sales of Hemlibra, Tecentriq, and Alecensa that was only partially offset by declines in Actemra and Edirol. Progress now for the year is now 43% of our full-year expectation of JPY 704 billion, with similar progress in operating income.